Cellectis SA (NASDAQ:CLLS)
| 18.24 Delayed Data As of Jan 17 |  -0.21 / -1.14%Today’s Change | 9.50 Today|||52-Week Range 20.84 | +6.54% Year-to-Date |
Latest CLLS News | Press Releases
| These Gene-Editing Pioneers Are Making Bold Bets in Agriculture Jan 18 / MotleyFool.com - Paid Partner Content | Why Iovance Biotherapeutics Shares Dropped 11.8% Today Jan 13 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 18.45 |
| Today’s open | 18.64 |
| Day’s range | 18.09 - 18.67 |
| Volume | 243,049 |
| Average volume (3 months) | 125,411 |
| Market cap | $773.4M |
Data as of 3:59pm ET, 01/17/2020
Growth & Valuation
| Earnings growth (last year) | +31.22% |
| Earnings growth (this year) | -28.28% |
| Earnings growth (next 5 years) | +1.50% |
| Revenue growth (last year) | -49.92% |
| P/E ratio | NM |
| Price/Sales | 53.38 |
| Price/Book | 1.89 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VCELVericel Corp | +0.04 | +0.23% |
| COLLCollegium Pharmaceut... | -0.51 | -2.13% |
| GNFTGenfit SA | -0.11 | -0.54% |
| PRVBProvention Bio Inc | +0.66 | +4.08% |
Data as of 4:00pm ET, 01/17/2020
Financials
| Next reporting date | March 16, 2020 |
| EPS forecast (this quarter) | -$0.74 |
| Annual revenue (last year) | $12.7M |
| Annual profit (last year) | -$78.6M |
| Net profit margin | -618.12% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Paris, Ile-de-france |
Forecasts
